Assess the Safety & Immunogenicity of Prime-Boost Vaccination Strategies Using H5Nx Virus Vaccine Adjuvanted With AS03 or MF59
Randomized, Double-Blinded, Phase 2 Study to Assess Safety and Immunogenicity of Homologous and Heterologous Prime-Boost Vaccination Strategies With Stockpiled Inactivated Monovalent Influenza A(H5) Vaccines Administered Intramuscularly With Either AS03 or MF59® as Adjuvant
Sponsor: Biomedical Advanced Research and Development Authority
A PHASE2 clinical study on Influenza A Virus, H5N1 Subtype, this trial is completed. The trial is conducted by Biomedical Advanced Research and Development Authority and has accumulated 11 data snapshots since 2018. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE2
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE2
▶ Show 6 earlier versions
-
Aug 2020 — Jan 2021 [monthly]
Completed PHASE2
-
May 2020 — Aug 2020 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Dec 2019 — May 2020 [monthly]
Active Not Recruiting PHASE2
-
Sep 2018 — Dec 2019 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Sep 2018 [monthly]
Recruiting PHASE2
-
May 2018 — Jun 2018 [monthly]
Recruiting PHASE2
First recorded
Mar 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Biomedical Advanced Research and Development Authority
For direct contact, visit the study record on ClinicalTrials.gov .